PortfoliosLab logoPortfoliosLab logo
PVLA vs. NTRA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PVLA vs. NTRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Palvella Therapeutics, Inc (PVLA) and Natera, Inc. (NTRA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PVLA achieves a 32.84% return, which is significantly higher than NTRA's 16.88% return.


PVLA

1D
-7.42%
1M
-5.26%
6M
81.30%
YTD
32.84%
1Y
280.41%
3Y*
5Y*
10Y*
ALL TIME*
329.85%

NTRA

1D
-0.70%
1M
-4.14%
6M
15.84%
YTD
16.88%
1Y
98.96%
3Y*
80.73%
5Y*
18.51%
10Y*
35.27%
ALL TIME*
25.25%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$246.10M$302.11M$352.98M
$30.14M$31.68M$34.01M

PVLA vs. NTRA - Yearly Performance Comparison


2026 (YTD)20252024
PVLA
Palvella Therapeutics, Inc
32.84%772.25%-8.27%
NTRA
Natera, Inc.
16.88%44.72%-4.95%

Correlation

The correlation between PVLA and NTRA is 0.29, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.29

Correlation (All Time)
Calculated using the full available price history since Dec 16, 2024

0.19

The correlation between PVLA and NTRA shifts across timeframes, from 0.19 (all time) to 0.29 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

PVLA:

$1.99B

NTRA:

$38.35B

EPS

PVLA:

-$3.74

NTRA:

-$1.63

PB Ratio

PVLA:

55.90

NTRA:

21.36

Total Revenue (TTM)

PVLA:

$0.00

NTRA:

$2.50B

Gross Profit (TTM)

PVLA:

$0.00

NTRA:

$1.63B

EBITDA (TTM)

PVLA:

-$14.75M

NTRA:

-$294.86M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PVLA vs. NTRA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

PVLA
PVLA Risk / Return Rank: 9696
Overall Rank
PVLA Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
PVLA Sortino Ratio Rank: 9595
Sortino Ratio Rank
PVLA Omega Ratio Rank: 9393
Omega Ratio Rank
PVLA Calmar Ratio Rank: 9898
Calmar Ratio Rank
PVLA Martin Ratio Rank: 9898
Martin Ratio Rank

NTRA
NTRA Risk / Return Rank: 9090
Overall Rank
NTRA Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
NTRA Sortino Ratio Rank: 9090
Sortino Ratio Rank
NTRA Omega Ratio Rank: 9090
Omega Ratio Rank
NTRA Calmar Ratio Rank: 9090
Calmar Ratio Rank
NTRA Martin Ratio Rank: 8787
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

PVLA vs. NTRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and Natera, Inc. (NTRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PVLANTRADifference
Sharpe ratioReturn per unit of total volatility

+1.03

Sortino ratioReturn per unit of downside risk

+0.61

Omega ratioGain probability vs. loss probability

1.42

1.36

+0.06

Calmar ratioReturn relative to maximum drawdown

9.07

3.58

+5.49

Martin ratioReturn relative to average drawdown

20.11

8.06

+12.05

PVLA vs. NTRA - Sharpe Ratio Comparison

The current PVLA Sharpe Ratio is 3.33, which is higher than the NTRA Sharpe Ratio of 2.30. The chart below compares the historical Sharpe Ratios of PVLA and NTRA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PVLA vs. NTRA - Drawdown Comparison

The maximum PVLA drawdown since its inception was -31.48%, smaller than the maximum NTRA drawdown of -77.74%. Use the drawdown chart below to compare losses from any high point for PVLA and NTRA.


Loading charts...

Drawdown Indicators


PVLANTRADifference

Max Drawdown

Largest peak-to-trough decline

-31.48%

-77.74%

+46.26%

Max Drawdown (1Y)

Largest decline over 1 year

-31.11%

-28.20%

-2.91%

Max Drawdown (3Y)

Largest decline over 3 years

-39.94%

Max Drawdown (5Y)

Largest decline over 5 years

-77.74%

Max Drawdown (10Y)

Largest decline over 10 years

-77.74%

Current Drawdown

Current decline from peak

-11.57%

-5.65%

-5.92%

Average Drawdown

Average peak-to-trough decline

-10.88%

-33.10%

+22.22%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.00%

12.50%

+1.50%

Volatility

PVLA vs. NTRA - Volatility Comparison

Palvella Therapeutics, Inc (PVLA) has a higher volatility of 33.15% compared to Natera, Inc. (NTRA) at 10.71%. This indicates that PVLA's price experiences larger fluctuations and is considered to be riskier than NTRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PVLANTRADifference

Volatility (1M)

Calculated over the trailing 1-month period

33.15%

10.71%

+22.44%

Volatility (6M)

Calculated over the trailing 6-month period

65.81%

36.89%

+28.92%

Volatility (1Y)

Calculated over the trailing 1-year period

84.76%

44.12%

+40.64%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.09%

57.04%

+27.05%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.09%

60.84%

+23.25%

Dividends

PVLA vs. NTRA - Dividend Comparison

Neither PVLA nor NTRA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PVLA vs. NTRA - Financials Comparison

This section allows you to compare key financial metrics between Palvella Therapeutics, Inc and Natera, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


PVLA and NTRA have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PVLA has higher volatility (33.15%) compared to NTRA (10.71%). In terms of maximum drawdown, PVLA dropped -31.48% vs NTRA's -77.74%.

PVLA currently has the higher Sharpe Ratio (3.33 vs 2.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PVLA and NTRA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer